Navigation Links
Kelyniam Global Inc. Reports 2011 3rd & 4th Quarter Financial Results
Date:2/16/2012

to common shareholders per share

$
(0.01)

(0.00)About Kelyniam Global, IncorporatedKelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at www.kelyniam.com for more information.

Forward-Looking StatementsExcept for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believes," "estimate," "expect," "should," "intend," "projects," "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

For Question regarding this Press Release, please contact:

Ke
'/>"/>

SOURCE Kelyniam Global Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kelyniam Makes History With Revolutionary 24-Hour Turnaround Capabilities
2. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
3. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
4. Directors Forum: PEPFAR and the Global AIDS Response
5. Alfacell Corporation to Present at UBS Global Life Sciences Conference
6. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
7. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
8. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
9. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
10. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
11. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
(Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... Pa., Dec. 7, 2011  Inovio Pharmaceuticals, Inc. (NYSE Amex: ... to fight cancers and infectious diseases, announced today that ... shares of its common stock and warrants to purchase ... which included the partial exercise of the underwriter,s overallotment ...
... -- The November 14, 2011, edition of ... Presence (VIP) as 4 stars ("would take it on ... Experiment (AEWE),s Spiral G at Fort Benning, GA, culminating ... and November 2011.  "It was a pleasure ...
Cached Medicine Technology:Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 2Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 3Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 4VIPAAR's VIP Earns 4-star Technology Rating at AEWE's Spiral G 2
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ( WEDI ... efficiencies in healthcare information exchange, announced the release of its findings from its June ... (HHS) Secretary, WEDI shared survey results and recommendations , strongly encouraging ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... to contract research organisations (CROs) for a slew of benefits, allowing them to ... and operations, boost quality with cost-effective utilisation of resources, get access to innovation ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bodybuilding.com, ... of nutritional supplements, has officially opened the polls for their eleventh annual ... following categories:, ,     Brand of the Year (BPI Sports) ...
(Date:8/3/2015)... ... August 03, 2015 , ... The art of preparing ... from her grandmother’s side at a young age, Nasreen Zereshki was extremely eager to ... to share her cookbook Recipes from My Persian Kitchen with the world. , Since ...
Breaking Medicine News(10 mins):Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2
... South Korea, July 20 HepaHope Korea ... owned subsidiary, VASKA, a Berkeley-based producer of green, botanically-based ... successfully turned the first major commercial laundry plant in the United ... South San Francisco is the largest privately owned commercial laundry on ...
... , CARY, N.C., July 20 ... company focused on acquiring, developing and commercializing products primarily for ... Executive Vice President, Finance, and Chief Financial Officer, has been ... in the Small Public Business category. Award recipients were ...
... CARLSBAD, Calif., July 20 SynergEyes, Inc., ... a new advanced lens design for keratoconus patients. ClearKone(TM) ... the best features of the hybrid platform, providing superior ... design is optimized to vault the predominant irregularities of ...
... , BANNOCKBURN, Ill., July 20 Heart disease is ... it,s often not until the untimely passing of a celebrity from a ... the issue is brought to the forefront of Americans, health and wellness ... a recent survey(2) uncovered that only 14 percent of people would be ...
... Population older than 65 could reach 1.3 billion by 2040 ... people who are age 65 and older will double from ... 2040, says a new U.S. Census Bureau study. , The ... last year to 1.3 billion in 30 years. The unprecedented ...
... PLAINS, N.Y. and CAMBRIDGE, Mass., July 20 The ... partnership to accelerate LLS,s pipeline of research projects entering late pre-clinical ... will begin with a selection of ten small molecule candidates, discovered ... of advancing into clinical trials in the shortest period of time. ...
Cached Medicine News:Health News:HepaHope Korea Subsidiary VASKA Introduces Green Chemicals to U.S. Commercial Laundry Industry 2Health News:Cornerstone Therapeutics' David Price Named 2009 Chief Financial Officer of the Year by the Triangle Business Journal 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 3Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 3Health News:Elder Boom Will Be Felt Worldwide 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 3
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,412-7) or contact custom...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... features: Eppendorf "pipette/tip" system ensures utmost ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: